Ab­b­Vie’s top ex­ecs paint a rosy pic of the mega-block­buster fu­ture loom­ing for Hu­mi­ra and PhI­II drugs

Ab­b­Vie’s top ex­ec­u­tive team has looked to the near fu­ture — and it is a fine and cheery place un­ham­pered by gener­ics or pric­ing pledges.

CEO Rick Gon­za­lez, CFO Bill Chase and CSO Michael Sev­eri­no sat down with Leerink’s Ge­of­frey Porges for a 90-minute dis­cus­sion about the com­pa­ny, giv­ing them a chance to out­line a bull­ish sce­nario for the next few years — which in­cludes some jaw-drop­ping fore­casts for its fran­chise drug Hu­mi­ra as well as its two top drugs in the late-stage pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER